Cargando…

Recommendations and Health Technology Assessment (HTA) landscape evaluation for pediatric pneumococcal conjugate vaccines (PCV) in Europe: A systematic literature review

National Immunization Technical Advisory Groups (NITAGs) and Health Technology Assessment (HTA) agencies evaluate the value of vaccines and provide decision-making authorities with recommendations. The availability of information on disease-burden evidence considered or required for the assessment o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bencina, Goran, Fues Wahl, Hanna, Tsoumani, Eleana, Salomonsson, Stina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Pneumococcal – Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897642/ https://www.ncbi.nlm.nih.gov/pubmed/35438039 http://dx.doi.org/10.1080/21645515.2022.2060017

Ejemplares similares

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population
por: Lytle, Derek, et al.
Publicado: (2023)

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
por: Gómez, Jorge A., et al.
Publicado: (2021)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
por: Izurieta, Patricia, et al.
Publicado: (2021)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
por: Simon, Michael W., et al.
Publicado: (2023)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)
por: Ishihara, Yasunori, et al.
Publicado: (2023)

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study
por: Haranaka, Miwa, et al.
Publicado: (2023)

Pneumonia hospitalizations and mortality in children 3 – 24-month-old in Nigeria from 2013 to 2020: Impact of pneumococcal conjugate vaccine ten valent (PHiD-CV-10)
por: Iliya, Jalo, et al.
Publicado: (2023)

A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age
por: Chu, Kai, et al.
Publicado: (2023)

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
por: Hammitt, Laura L., et al.
Publicado: (2023)

Regional factors associated with pneumococcal vaccination coverage among U.S. adults with underlying chronic or immunocompromising conditions
por: Liu, Junqing, et al.
Publicado: (2023)

A pediatric case series of invasive pneumococcal disease caused by S.Pneumonia serotype-19A despite full dose vaccination
por: Cura Yayla, Burcu Ceylan, et al.
Publicado: (2023)

Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media
por: Izurieta, Patricia, et al.
Publicado: (2022)

Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020
por: Guzman-Holst, Adriana, et al.
Publicado: (2021)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
por: Bencina, Goran, et al.
Publicado: (2023)

Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial
por: Pan, Lu-Lu, et al.
Publicado: (2022)

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
por: Sabharwal, Charu, et al.
Publicado: (2022)

Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong
por: Mohanty, Salini, et al.
Publicado: (2022)

Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt
por: Sevilla, JP, et al.
Publicado: (2022)

A narrative review on vaccination rate and factors associated with the willingness to receive pneumococcal vaccine in Chinese adult population
por: Yunhua, Bai, et al.
Publicado: (2022)

Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China
por: Hu, Yu, et al.
Publicado: (2022)

Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions
por: Edmondson-Jones, Mark, et al.
Publicado: (2021)

A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia
por: Lagoubi, Youness, et al.
Publicado: (2022)

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial
por: Wang, Wenjuan, et al.
Publicado: (2022)

Economic burden of pneumococcal disease in children in Liguria, Italy
por: Amicizia, Daniela, et al.
Publicado: (2022)

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)
por: Severance, Randall, et al.
Publicado: (2021)

Pneumonia hospitalizations of children aged <2 years in Poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine
por: Bhavsar, Amit, et al.
Publicado: (2022)

The impact of COVID-19 on routine vaccinations in Taiwan and an unexpected surge of pneumococcal vaccination
por: Chiu, Nan-Chang, et al.
Publicado: (2022)

Factors influencing acceptance of influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease
por: Saiphoklang, Narongkorn, et al.
Publicado: (2022)

Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
por: Nymark, Liv Solvår, et al.
Publicado: (2022)

Clinical and economic burden of pneumococcal disease among adults in Sweden: A population-based register study
por: Zarabi, Natalie, et al.
Publicado: (2023)

Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 – April 2019
por: Liapikou, Adamantia, et al.
Publicado: (2022)

Reply letter to “response to article by Johnna Perdrizet et al.” by Gomez and colleagues
por: Perdrizet, Johnna, et al.
Publicado: (2021)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
por: Ansaldi, Filippo, et al.
Publicado: (2020)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany
por: van der Linden, Mark, et al.
Publicado: (2016)

Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia
por: Suwantika, Auliya A., et al.
Publicado: (2020)

Hospitalization costs for children with pneumonia in Shanghai, China from 2019 to 2020
por: Wang, Jing, et al.
Publicado: (2022)

Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic
por: Tomczyk, Sara, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gn84krptjta2eslfg9neclovr8